Gerard J. Michel

This profile gathers the share dealings of Gerard J. Michel across 4 companies, led by Vericel Corp, Delcath Systems, Inc. and Albireo Pharma, Inc. The record holds 76 filings, for trades running from 8 February 2011 to 21 May 2026.

Market trades split into 16 purchases (€1.4M) and 19 sales (€2.5M). Sales outweigh purchases by €1.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 9 share grants and 32 option exercises. In 2026 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €83k. Clusters matter here: 8 out of 15 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 26 May 2026, the filings show a share grant in Beta Bionics, Inc. The latest purchase dates back some time: it was published 235 days ago, on 3 March 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.